BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 1355219)

  • 1. Efficacy and toxicity of eflornithine for treatment of Trypanosoma brucei gambiense sleeping sickness.
    Milord F; Pépin J; Loko L; Ethier L; Mpia B
    Lancet; 1992 Sep; 340(8820):652-5. PubMed ID: 1355219
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Treatment of sleeping disease caused by trypanosoma brucei gambiense with alpha-difluoromethylornithine (DFMO) in a rural hospital in Zaire].
    De Groof D; Bruneel H; Musumari TS; Ruppol JF
    Med Trop (Mars); 1992; 52(4):369-75. PubMed ID: 1494306
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Eflornithine concentrations in serum and cerebrospinal fluid of 63 patients treated for Trypanosoma brucei gambiense sleeping sickness.
    Milord F; Loko L; Ethier L; Mpia B; Pépin J
    Trans R Soc Trop Med Hyg; 1993; 87(4):473-7. PubMed ID: 8249087
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Difluoromethylornithine for arseno-resistant Trypanosoma brucei gambiense sleeping sickness.
    Pepin J; Milord F; Guern C; Schechter PJ
    Lancet; 1987 Dec; 2(8573):1431-3. PubMed ID: 2891995
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nifurtimox-eflornithine combination therapy for second-stage African Trypanosoma brucei gambiense trypanosomiasis: a multicentre, randomised, phase III, non-inferiority trial.
    Priotto G; Kasparian S; Mutombo W; Ngouama D; Ghorashian S; Arnold U; Ghabri S; Baudin E; Buard V; Kazadi-Kyanza S; Ilunga M; Mutangala W; Pohlig G; Schmid C; Karunakara U; Torreele E; Kande V
    Lancet; 2009 Jul; 374(9683):56-64. PubMed ID: 19559476
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Advances in sleeping sickness therapy.
    Van Nieuwenhove S
    Ann Soc Belg Med Trop; 1992; 72 Suppl 1():39-51. PubMed ID: 1417168
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mortality trends and risk factors in advanced stage-2 Human African Trypanosomiasis: A critical appraisal of 23 years of experience in the Democratic Republic of Congo.
    Kazumba LM; Kaka JT; Ngoyi DM; Tshala-Katumbay D
    PLoS Negl Trop Dis; 2018 Jun; 12(6):e0006504. PubMed ID: 29897919
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High-dose nifurtimox for arseno-resistant Trypanosoma brucei gambiense sleeping sickness: an open trial in central Zaire.
    Pépin J; Milord F; Meurice F; Ethier L; Loko L; Mpia B
    Trans R Soc Trop Med Hyg; 1992; 86(3):254-6. PubMed ID: 1412646
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of human late stage gambiense trypanosomiasis with alpha-difluoromethylornithine (eflornithine): efficacy and tolerance in 14 cases in Côte d'Ivoire.
    Doua F; Boa FY; Schechter PJ; Miézan TW; Diai D; Sanon SR; De Raadt P; Haegele KD; Sjoerdsma A; Konian K
    Am J Trop Med Hyg; 1987 Nov; 37(3):525-33. PubMed ID: 3120607
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [A trial treatment with eflornithine of trypanosomiasis caused by Trypanosoma brucei gambiense in the Peoples Republic of the Congo].
    Eozenou P; Jannin J; Ngampo S; Carme B; Tell GP; Schechter PJ
    Med Trop (Mars); 1989; 49(2):149-54. PubMed ID: 2507863
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The pharmacokinetics of eflornithine (alpha-difluoromethylornithine) in patients with late-stage T.b. gambiense sleeping sickness.
    Na-Bangchang K; Doua F; Konsil J; Hanpitakpong W; Kamanikom B; Kuzoe F
    Eur J Clin Pharmacol; 2004 Jun; 60(4):269-78. PubMed ID: 15141331
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Treatment of human trypanosomiasis caused by Trypanosoma brucei gambiense using alpha-difluoromethylornithine. Results in 7 patients].
    Taelman H; Marcelis L; Sonnet J; Kazyumba G; Van den Enden E; Wery M; Schechter PJ
    Bull Soc Pathol Exot Filiales; 1988; 81(3 Pt 2):578-88. PubMed ID: 3143491
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Melarsoprol versus eflornithine for treating late-stage Gambian trypanosomiasis in the Republic of the Congo.
    Balasegaram M; Harris S; Checchi F; Ghorashian S; Hamel C; Karunakara U
    Bull World Health Organ; 2006 Oct; 84(10):783-91. PubMed ID: 17128358
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of gambiense sleeping sickness in the Sudan with oral DFMO (DL-alpha-difluoromethylornithine), an inhibitor of ornithine decarboxylase; first field trial.
    Van Nieuwenhove S; Schechter PJ; Declercq J; Boné G; Burke J; Sjoerdsma A
    Trans R Soc Trop Med Hyg; 1985; 79(5):692-8. PubMed ID: 3938090
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oral fexinidazole for late-stage African Trypanosoma brucei gambiense trypanosomiasis: a pivotal multicentre, randomised, non-inferiority trial.
    Mesu VKBK; Kalonji WM; Bardonneau C; Mordt OV; Blesson S; Simon F; Delhomme S; Bernhard S; Kuziena W; Lubaki JF; Vuvu SL; Ngima PN; Mbembo HM; Ilunga M; Bonama AK; Heradi JA; Solomo JLL; Mandula G; Badibabi LK; Dama FR; Lukula PK; Tete DN; Lumbala C; Scherrer B; Strub-Wourgaft N; Tarral A
    Lancet; 2018 Jan; 391(10116):144-154. PubMed ID: 29113731
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [The use of difluoromethylornithine in congenital trypanosomiasis due to Trypanosoma brucei-gambiense].
    Pepin J; Guern C; Milord F; Ethier L; Bokelo M; Schechter PJ
    Med Trop (Mars); 1989; 49(1):83-5. PubMed ID: 2498607
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A multicentre, randomised, non-inferiority clinical trial comparing a nifurtimox-eflornithine combination to standard eflornithine monotherapy for late stage Trypanosoma brucei gambiense human African trypanosomiasis in Uganda.
    Kansiime F; Adibaku S; Wamboga C; Idi F; Kato CD; Yamuah L; Vaillant M; Kioy D; Olliaro P; Matovu E
    Parasit Vectors; 2018 Feb; 11(1):105. PubMed ID: 29471865
    [TBL] [Abstract][Full Text] [Related]  

  • 18. African sleeping sickness in the United States. Successful treatment with eflornithine.
    Petru AM; Azimi PH; Cummins SK; Sjoerdsma A
    Am J Dis Child; 1988 Feb; 142(2):224-8. PubMed ID: 3124603
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nifurtimox-eflornithine combination therapy for second-stage Trypanosoma brucei gambiense sleeping sickness: a randomized clinical trial in Congo.
    Priotto G; Kasparian S; Ngouama D; Ghorashian S; Arnold U; Ghabri S; Karunakara U
    Clin Infect Dis; 2007 Dec; 45(11):1435-42. PubMed ID: 17990225
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In-hospital safety in field conditions of nifurtimox eflornithine combination therapy (NECT) for T. b. gambiense sleeping sickness.
    Schmid C; Kuemmerle A; Blum J; Ghabri S; Kande V; Mutombo W; Ilunga M; Lumpungu I; Mutanda S; Nganzobo P; Tete D; Mubwa N; Kisala M; Blesson S; Mordt OV
    PLoS Negl Trop Dis; 2012; 6(11):e1920. PubMed ID: 23209861
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.